How Labcorp Holdings Inc. Makes Money

Yet the path forward is fraught: routine diagnostic testing faces pricing pressure from Medicare reimbursement cuts and commercial payer cost management; the biopharma segment depends on pharmaceutical R&D spending that fluctuates with drug development cycles; and Quest Diagnostics remains a formidable competitor with comparable scale and a similar strategic direction. Routine tests have lower margins but higher volume, while specialty tests command premium pricing but require specialized equipment and expertise. The company faces ongoing pricing pressure from Medicare reimbursement cuts, including the Protecting Access to Medicare Act (PAMA) which reduced clinical laboratory fee schedule rates. Mayo Clinic Laboratories leverages the Mayo Clinic's clinical reputation to command premium pricing for complex diagnostic testing. Labcorp's most immediate challenge is the pricing pressure on routine diagnostic testing from Medicare reimbursement cuts. The Protecting Access to Medicare Act (PAMA) has reduced clinical laboratory fee schedule rates, and further cuts are possible as Congress seeks healthcare cost savings. This commoditization pressure limits pricing power and requires continuous cost optimization to maintain margins. Quest has been equally aggressive in specialty testing expansion and health system partnerships, creating a duopolistic competitive dynamic where pricing and market share battles are fought test by test, contract by contract. Specialty tests command premium pricing and higher margins, offsetting routine testing commoditization. Long-term, Labcorp must prove it can maintain pricing power in routine testing while building higher-margin specialty and data services that justify a premium valuation relative to commodity laboratory peers.

CEO Adam Schechter, who took the helm in November 2019, has bet Labcorp's future on three pillars: expanding specialty testing in oncology, women's health, neurology, and autoimmune diseases; building health system partnerships through lab management agreements and acquisitions; and using the company's longitudinal diagnostic data from more than 75 million patients to improve health outcomes and reduce treatment costs. The 2024 acquisition of select Invitae assets advanced the specialty testing strategy, while partnerships with Baystate Health and Providence expanded the health system footprint. The stakes are clear: Labcorp must prove it can grow faster than the commoditizing routine testing market while building higher-margin specialty and biopharma services that justify its strategic premium. Under CEO Adam Schechter since 2019, Labcorp has pursued specialty testing expansion, health system partnerships, and operational efficiency through its LaunchPad initiative. Revenue flows from specimen collection (through patient service centers, phlebotomists, and hospital partnerships), laboratory processing (at primary laboratories and specialized facilities), and result reporting. In 2024, Labcorp launched more than 130 innovative new tests, expanding its menu in high-growth therapeutic areas. CEO Adam Schechter has guided the company toward 5.4% revenue growth and 8.9% adjusted EPS growth in 2026, targets that assume successful execution of specialty testing expansion, health system partnership growth, and operational efficiency initiatives. PPD, acquired by Thermo Fisher in 2021, offers central laboratory and clinical development services. Labcorp's competitive response includes acquiring specialized capabilities (Invitae assets for genetic testing) and building internal expertise in high-growth areas. The health system partnership market is increasingly competitive, with both Labcorp and Quest pursuing lab management agreements and outreach acquisitions. The revenue growth was driven by organic growth of approximately 4.4%, acquisitions net of divestitures contributing 2.5%, and foreign currency translation adding 0.4%. Routine testing represents the volume base of Labcorp's Diagnostics segment, and margin compression in this category threatens overall profitability if not offset by specialty testing growth and cost reductions. Fifth, the 2023 Fortrea spin-off removed a significant revenue stream — clinical development and commercialization services — that had been acquired through the 2015 Covance purchase. While the spin-off created a more focused company, it also reduced revenue diversification and eliminated cross-selling opportunities between diagnostics and clinical development. Any FDA regulation of LDTs could increase compliance costs and delay test launches. While Labcorp has partnerships with consumer health companies, the trend toward at-home testing and wearable diagnostics could reduce demand for centralized laboratory services over the long term. The 2024 acquisition of select Invitae assets strengthened oncology and rare disease genetic testing, while internal development has expanded the test menu by more than 130 innovative tests annually. Fourth, health system partnerships and lab management agreements create sticky relationships that reduce customer churn. Sixth, Labcorp's LaunchPad operational excellence initiative has generated significant cost savings through process automation, supply chain optimization, and organizational efficiency. These savings improve margins and provide funding for growth investments. Labcorp's growth strategy under CEO Adam Schechter centers on four pillars: specialty testing expansion, health system partnerships, operational excellence, and strategic acquisitions. The first pillar concentrates resources on high-growth testing categories including oncology (companion diagnostics, liquid biopsy, tumor profiling), women's health (prenatal screening, reproductive genetics), neurology (Alzheimer's biomarkers, autoimmune neurology), and autoimmune diseases. In 2024, LaunchPad savings contributed to margin improvement despite PAMA reimbursement headwinds. The fourth pillar, strategic acquisitions, focuses on tuck-in deals that expand specialty capabilities or geographic presence. The company has also announced a strategic investment to build a modern 500,000 square foot Central Laboratory facility to address growth demand. Capital allocation balances growth investments with shareholder returns, with 2025 guidance including continued share repurchases and dividend maintenance. Labcorp's strategic horizon is defined by three concurrent imperatives: growing specialty testing faster than routine testing commoditizes, expanding health system partnerships to secure volume, and building data and analytics capabilities that use its longitudinal patient information. Specialty testing is the dominant near-term growth driver. Health system partnerships represent a second growth pillar. These partnerships convert independent hospital laboratories into Labcorp-managed operations, securing long-term volume and reducing competitive pressure. The strategy targets health systems seeking to reduce laboratory costs without investing in independent scale. The company is also investing in a modern, state-of-the-art 500,000 square foot Central Laboratory facility to address growth in demand and improve operational efficiency. Capital allocation will continue to prioritize acquisitions that expand specialty capabilities or health system relationships, share repurchases, and dividends. In the late 1990s and early 2000s, Labcorp expanded through organic growth and acquisitions, building a national network of patient service centers and primary laboratories. These acquisitions expanded Labcorp's test menu beyond routine chemistry and hematology into higher-margin, higher-complexity testing categories. The spin-off reversed the diversification strategy that had driven the Covance acquisition, reflecting management's view that diagnostics and clinical development were distinct businesses with different capital requirements, growth profiles, and competitive dynamics. The company continued its acquisition strategy with the purchase of select Invitae assets (advancing specialty testing in oncology and rare diseases) and BioReference Health's diagnostic business (expanding clinical diagnostics and reproductive health capabilities).